Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 5/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 7/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30063042 | 0.89 | PTGER2 (0.46) | PTGER2PTGER4NAMPTTP53MAPT | |
| SCHEMBL533073 | 0.89 | PTGER2 (0.46) | PTGER2PTGER4NAMPTTP53MAPT | |
| SCHEMBL533447 | 0.88 | PTGER2 (0.48) | PTGER2PTGER4NAMPTTP53MAPT | |
| Hydrochloric Acid SCHEMBL533633 | 0.86 | PTGER2 (0.64) | PTGER2PTGER4 | |
| SCHEMBL533246 | 0.86 | PTGER2 (0.64) | PTGER2PTGER4 | |
| SCHEMBL20262519 | 0.85 | PTGER2 (0.67) | PTGER2PTGER4NAMPT | |
| SCHEMBL29391537 | 0.85 | PTGER2 (0.67) | PTGER2PTGER4NAMPT | |
| SCHEMBL11026034 | 0.85 | PTGER2 (0.49) | PTGER2PTGER4NAMPTTP53MAPT | |
| SCHEMBL533546 | 0.85 | PTGER2 (0.47) | PTGER2PTGER4NAMPTTP53MAPT | |
| SCHEMBL18204450 | 0.85 | PTGER2 (0.46) | PTGER2PTGER4NAMPTTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110251516-B | Pharmaceutical composition comprising pyridylamino acetic acid compound and polyoxyethylated castor oil | 参天制药株式会社 | 2022-05-03 | — | — | CN | claimed |
| CN-107708738-B | Depot formulations containing citrate esters | 参天制药株式会社 | 2022-03-25 | — | — | CN | claimed |
| CN-108743587-B | Pharmaceutical preparation containing pyridylamino acetic acid compound | 参天制药株式会社 | 2021-04-30 | — | — | CN | claimed |
| EP-3750541-A1 | PHARMACEUTICAL PREPARATION CONTAINING PYRIDYLAMINOACETIC ACID COMPOUND | Santen Pharmaceutical Co., Ltd (JP) | 2020-12-16 | — | — | EP | claimed |
| EP-3424503-B1 | PHARMACEUTICAL PREPARATION INCLUDING PYRIDYLAMINO ACETIC ACID COMPOUND | SANTEN PHARMACEUTICAL CO LTD (JP) | 2020-09-02 | — | — | EP | claimed |
| US-20200206200-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT CONTAINING PYRIDYLAMINOACETIC ACID COMPOUND | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2020-07-02 | — | — | US | claimed |
| CN-105828818-B | Pharmaceutical compositions containing pyridylamino acetic acid compounds | 参天制药株式会社 | 2020-06-02 | — | — | CN | claimed |
| EP-3424503-A1 | PHARMACEUTICAL PREPARATION INCLUDING PYRIDYLAMINO ACETIC ACID COMPOUND | Santen Pharmaceutical Co., Ltd (JP) | 2019-01-09 | — | — | EP | claimed |
| EP-3093018-B1 | PHARMACEUTICAL PREPARATION INCLUDING PYRIDYLAMINO ACETIC ACID COMPOUND | SANTEN PHARMACEUTICAL CO LTD (JP) | 2018-11-28 | — | — | EP | claimed |
| EP-3320904-A1 | PREVENTATIVE AND/OR THERAPEUTIC AGENT CONTAINING PYRIDYL AMINOACETIC ACID COMPOUND | Santen Pharmaceutical Co., Ltd. (JP) | 2018-05-16 | — | — | EP | claimed |
| EP-3093018-A1 | PHARMACEUTICAL PREPARATION INCLUDING PYRIDYLAMINO ACETIC ACID COMPOUND | Santen Pharmaceutical Co., Ltd (JP) | 2016-11-16 | — | — | EP | claimed |
| US-20160324838-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING A PYRIDYLAMINOACETIC ACID COMPOUND | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2016-11-10 | — | — | US | claimed |
| US-20160228421-A1 | COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA COMPRISING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | claimed |
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | claimed |
| US-20140018396-A1 | COMBINATION OF SULFONAMIDE COMPOUND | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-01-16 | — | — | US | claimed |
| US-11974994-B2 | Agent for treating or preventing glaucoma including a sulfonamide compound and another drug | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2024-05-07 | — | — | US | disclosed |
| EP-3320904-B1 | PREVENTATIVE AND/OR THERAPEUTIC AGENT CONTAINING PYRIDYL AMINOACETIC ACID COMPOUND FOR TREATING A DISEASE INVOLVING A GREATLY ELEVATED INTRAOCULAR PRESSURE | SANTEN PHARMACEUTICAL CO LTD (JP) | 2023-07-05 | — | — | EP | disclosed |
| US-9339496-B2 | Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2016-05-17 | — | — | US | disclosed |
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | disclosed |
| US-20140018396-A1 | COMBINATION OF SULFONAMIDE COMPOUND | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324838-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING A PYRIDYLAMINOACETIC ACID COMPOUND | PTGIS, UACA, PTGIR | PTGER2 426/4885PTGER4 725/4885NAMPT 607/4885 |
| US-20140018396-A1 | COMBINATION OF SULFONAMIDE COMPOUND | CHUK, PTGIS, PTGIR | PTGER2 58/4885PTGER4 78/4885NAMPT 1550/4885 |
| US-20160228421-A1 | COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA COMPRISING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | PTGIS, PTGIR, PTGS1 | PTGER2 6/4885PTGER4 25/4885NAMPT 921/4885 |
| US-11974994-B2 | Agent for treating or preventing glaucoma including a sulfonamide compound and another drug | PTGIS, PTGIR, PTGS1 | PTGER2 13/4885PTGER4 51/4885NAMPT 825/4885 |
| US-20200206200-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT CONTAINING PYRIDYLAMINOACETIC ACID COMPOUND | AADAC, AADAT, PLPBP | PTGER2 1073/4885PTGER4 2062/4885NAMPT 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.